The effects of tibolone

Review OA: closed public-domain-us
View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-22 ⓘ

Tibolone, a non-bleeding hormone replacement therapy that induces endometrial atrophy via progestogenic metabolites, offers clinical utility for postmenopausal women and those with a history of endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Tibolone is a non-bleeding form of hormone replacement therapy (HRT). When ingested, it is broken down into metabolites, of which the progestogenic metabolite predominates at the level of the endometrium, so that an atrophic endometrium is produced. For the postmenopausal woman, the availability of non-bleeding HRT has great appeal, and compliance is substantially improved. Other clinical situations in which tibolone is particularly useful include: women who have had hormone-dependent tumors in the past, women who have had endometriosis and women taking gonadotropin-releasing hormone agonists.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Estrogen Replacement Therapy Estrogen Replacement Therapy Norpregnenes Female Female Humans Humans Norpregnenes Norpregnenes

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-19T06:17:24.038039+00:00
pubmed
last seen: 2026-10-08T22:00:41.816812+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine